Emerging evidence · Grade B
Thymalin
Thymalin (Thymic Bioregulator Peptide Complex)
Score
60 / 100
Source
Thymus extract (Russia)
Type
Peptide mixture
Status
Rx in Russia; investigational elsewhere
TL;DR
01
A polypeptide complex extracted from thymus tissue, developed in the Soviet Union/Russia by Vladimir Khavinson and used there as an immunomodulator.
02
Unlike the single, defined peptide thymosin alpha-1, thymalin is a mixture — its exact active composition is not fully specified.
03
In cell studies it pushes stem cells toward mature immune (T) cells, which is the basis for its immune-support claims, including proposed use in respiratory infections.
04
The evidence is largely Russian and from the developing group, without independent Western randomized trials, so it sits well below thymosin alpha-1 on evidence quality.
05
It is not FDA-approved; outside Russia it is a research-grade product.
Russian clinical use
Yes
immunomodulator
Independent Western RCTs
None
evidence largely single-group
Composition
Undefined mixture
not a single peptide
Mechanism (cell)
T-cell differentiation
HSC → CD28 T cells
FDA
Not approved
research-grade elsewhere
Part 01 · How it works
Mechanism.
Thymalin is a mixture of peptides pulled from thymus tissue, meant to do what the thymus does — help the immune system mature and balance itself. In laboratory work it nudges blood stem cells to become mature T cells, which supports its use in Russia as an immune booster, including proposals for respiratory infections. The two big caveats: it's an undefined mixture rather than a single characterized drug, and its human evidence comes largely from the Russian group that developed it, without independent international trials to confirm it.
A thymus-in-a-vial extract that, in the lab, helps immune cells mature — used in Russia, but not independently confirmed and not a single defined drug like thymosin alpha-1.
Thymic peptide complex
A polypeptide fraction from thymus tissue; active components not fully defined.
Immune differentiation
In vitro, shifts hematopoietic stem cells toward mature CD28+ T lymphocytes.
Proposed applications
Immunopathology and respiratory infections in Russian clinical use.
Evidence stage
Russian clinical use + cell studies; no independent Western RCTs.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for Thymalin. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Standard dose
10 mg (lower-end 5 mg)
Intramuscular injection (subcutaneous also used) · Once daily
Duration
5–10 day course, repeated every 3–6 months
·
Best clinically-supported of the bioregulator cluster: 10 mg IM daily for 5–10 days matches Khavinson-program Russian trials and a recent severe-COVID RCT — but this is Russian clinical practice, not international labeling.
·
Given by injection (IM/SC) in short courses; a 10 mg vial is typically reconstituted to ~5 mg/mL.
·
Outside Russia it is an unregulated research-grade product with no purity/dose guarantee.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Injection-site reactions
Generally mild.
Occasional
Serious · rare
Immune modulation
Theoretical caution in autoimmune disease.
Consideration
Undefined-mixture / quality risk
Composition not fully specified; purity varies by source.
Source-dependent
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18 (unless under immunology specialist care)
×
Known hypersensitivity to thymalin, thymic extract, or any component
×
Organ transplant recipients on immunosuppression (may trigger rejection)
×
Active autoimmune disease in flare
Relative · discuss first
!
Autoimmune disease — immune-modulating mechanism, caution
!
Pregnancy or breastfeeding — insufficient data
!
Anyone needing internationally validated efficacy — not established
Interactions
Immunosuppressants (tacrolimus, cyclosporine, mycophenolate)
Thymalin stimulates T-cell immunity; directly opposes immunosuppressive therapy and may trigger graft rejection
Major
Immune checkpoint inhibitors (nivolumab, pembrolizumab)
Additive immune activation; may increase risk of immune-related adverse events
Moderate
Corticosteroids
High-dose corticosteroids suppress thymic function and may reduce thymalin efficacy
Moderate
Labs to monitor
CBC with Differential
Baseline and monthly
Monitor immune cell populations (T-cell focus)
T-Cell Subsets (CD4, CD8, CD4/CD8 ratio)
Baseline and at end of cycle
Primary target of thymic bioregulator
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
General metabolic safety
Immunoglobulin Levels
Baseline and at end of cycle
Assess humoral immune response
Part 04 · Evidence
How strong is the evidence?
60
Grade B
Grade B, Emerging. Thymalin has plausible immune biology and clinical use in Russia, but it is an undefined mixture with evidence concentrated in the originating group and no independent Western trials — a clear step below thymosin alpha-1.
Mechanistic plausibility
Thymic immunomodulation is plausible, but the mixture is poorly defined.
70
Human evidence
Russian clinical use; no independent international RCTs.
48
Safety & tolerability
Long Russian use with a benign profile; independent data limited.
70
Durability
Not established by independent long-term data.
55
Independence
Evidence concentrated in the developing (Khavinson) group.
42
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2020
Bull Exp Biol Med Flagged
Thymalin: activation of differentiation of human hematopoietic stem cells
Thymalin reduced stem-cell markers (CD44, CD117) and increased the mature T-cell marker CD28 ~6.8-fold, indicating stimulation of HSC differentiation into mature T lymphocytes; proposed as COVID immunoprotection.
Human HSC cell-culture study · Cell study from the originating group; mechanistic, not clinical outcome evidence.
PMID 33237528 ↗
Moderate (preclinical)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Undefined mixture with single-group, non-Western evidence
Mechanism limit Bull Exp Biol Med · 2020
Thymalin is a poorly defined peptide mixture, and its clinical evidence is largely Russian and from the developing group, without independent Western randomized trials confirming benefit.
What this means: It should not be equated with the defined, internationally studied thymosin alpha-1. Its efficacy is not independently established.
PMID 33237528 ↗
Part 06 · Cost & access
Where it's available, at what price.
Russia
Approved
Prescribed immunomodulator.
Russian market
United States
Not approved
Not FDA-approved; research-grade.
Grey-market; unregulated
European Union
Not approved
Not approved.
N/A
United Kingdom
Not approved
Not approved.
N/A
The Peptide Column takes no affiliate commission from any source. Thymalin is used in Russia but not FDA-approved; outside Russia it is an unregulated research-grade mixture with no independent efficacy evidence. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Has Thymalin been studied in populations comparable to mine, and are those studies published in peer-reviewed journals accessible outside Russia?
02
Could Thymalin worsen autoimmune conditions by stimulating immune activity?
03
How does Thymalin compare to Thymosin Alpha-1 (Zadaxin) in terms of evidence and regulatory status?
04
What immune biomarkers should be measured before and during treatment?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Thymalin: activation of differentiation of human hematopoietic stem cells · Bull Exp Biol Med, 2020 · PMID 33237528 ↗
- 02. St. Petersburg Institute of Bioregulation and Gerontology. Khavinson thymalin research